Dr Raffi H Kadian, DPM | |
Rte 903 Pine Point Plaza, Suite 601, Albrightsville, PA 18210-0163 | |
(570) 722-1238 | |
(215) 236-8206 |
Full Name | Dr Raffi H Kadian |
---|---|
Gender | Male |
Speciality | Podiatrist |
Location | Rte 903 Pine Point Plaza, Albrightsville, Pennsylvania |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023210705 | NPI | - | NPPES |
13585 | Other | PA | HEALTH PARTNERS |
0011322000011 | Medicaid | PA | |
1001055 | Other | PA | KEYSTONE MERCY HEALTH PLA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | SC003243L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Raffi H Kadian, DPM Po Box 163, Rte 903 Pine Point Plaza Suite 601, Albrightsville, PA 18210-0163 Ph: (570) 722-1238 | Dr Raffi H Kadian, DPM Rte 903 Pine Point Plaza, Suite 601, Albrightsville, PA 18210-0163 Ph: (570) 722-1238 |
News Archive
Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.
Bluegrass Vascular Technologies, a medical technology company focused on life-saving devices and methods for vascular access procedures, has announced patient enrollment in the first clinical study of its Surfacer Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel "inside-out" approach to gain venous access.
It has taken three years but at last the the controversial morning after pill, Plan B will finally be available to women in the U.S. without a prescription.
Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the EPO's Technical Board of Appeals.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 6 days ago